Essential fatty acids for premenstrual syndrome and their effect on prolactin and total cholesterol levels: a randomized, double blind, placebo-controlled study.
OBJECTIVE
To evaluate the effectiveness and safety of polyunsaturated fatty acids for the treatment of the premenstrual syndrome (PMS) using a graded symptom scale and to assess the effect of this treatment on basal plasma levels of prolactin and total cholesterol.


METHODS
A randomized, double-blind, placebo-controlled study was conducted with 120 women with PMS divided into three groups and treated with 1 or 2 grams of the medication or placebo. Symptoms were recorded over a 6-month period using the Prospective Record of the Impact and Severity of Menstruation (PRISM) calendar. Total cholesterol and prolactin levels were measured. Analysis of variance (ANOVA), Pearson's chi-square test, Wilcoxon's nonparametric signed-rank test for paired samples and the Mann-Whitney nonparametric test for independent samples were used in the statistical analysis.


RESULTS
There were no differences in age, marital status, schooling or ethnicity between the groups. In the group treated with 1 gram of the medication, a significant reduction was found when the median PRISM score recorded in the luteal phase at baseline (99) was compared with the median score recorded in the 3rd month (58) and in the 6th month of evaluation (35). In the 2-gram group, these differences were even more significant (baseline score: 98; 3rd month: 48; 6th month: 28). In the placebo group, there was a significant reduction at the 3rd but not at the 6th month (baseline: 96.5; 3rd month: 63.5; 6th month: 62). The difference between the phases of the menstrual cycle was greater in the 2-gram group compared to the group treated with 1 gram of the medication. There were no statistically significant differences in prolactin or total cholesterol levels between baseline values and those recorded after six months of treatment.


CONCLUSIONS
The difference between the groups using the medication and the placebo group with respect to the improvement in symptomatology appears to indicate the effectiveness of the drug. Improvement in symptoms was higher when the 2-gram dose was used. This medication was not associated with any changes in prolactin or total cholesterol levels in these women.
Department of Maternal and Child Healthcare, School of Medicine, Federal University of Pernambuco, Recife, Pernambuco, Brazil. edilbertorocha@globo.com
Edilberto A
EA
Rocha Filho
José C
JC
Lima
João S
JS
Pinho Neto
Ulisses
U
Montarroyos
D000293:Adolescent; D000328:Adult; D002784:Cholesterol / Q000097:blood*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005228:Fatty Acids, Essential / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008597:Menstrual Cycle / Q000502:physiology; D011293:Premenstrual Syndrome / Q000097:blood / Q000188:drug therapy*; D011388:Prolactin / Q000097:blood* / Q000187:drug effects; D012720:Severity of Illness Index; D016896:Treatment Outcome; D055815:Young Adult
D005228:Fatty Acids, Essential; D011388:Prolactin; D002784:Cholesterol
Am J Obstet Gynecol. 1981 Jan;139(1):85-104
7006400
Biol Psychiatry. 1994 Apr 15;35(8):557-61
8038300
J Occup Environ Med. 2004 Jul;46(7):649-56
15247803
Fertil Steril. 1990 Nov;54(5):757-71
2226908
Expert Opin Pharmacother. 2003 Nov;4(11):2065-78
14596660
J Reprod Med. 1983 Jul;28(7):446-64
6684167
Int J Gynaecol Obstet. 1995 Jul;50(1):80-4
7556868
J Clin Endocrinol Metab. 1991 Mar;72(3):642-6
1997519
Rev Pure Appl Pharmacol Sci. 1983 Oct-Dec;4(4):339-83
6400557
J Clin Endocrinol Metab. 1991 Feb;72(2):250-1
1846867
Am J Obstet Gynecol. 1987 Oct;157(4 Pt 1):964-8
3674170
Can J Psychiatry. 2002 Nov;47(9):888-9
12500764
Nutr Neurosci. 2006 Feb-Apr;9(1-2):1-10
16910164
Clin Obstet Gynecol. 1992 Sep;35(3):599-611
1521388
Obstet Gynecol Clin North Am. 2009 Dec;36(4):907-24, xii
19944308
Med Care. 2002 Nov;40(11):1101-12
12409855
Acta Obstet Gynecol Scand. 1993 Jul;72(5):337-43
8392261
J Affect Disord. 2005 Apr;85(3):317-21
15780701
Obstet Gynecol. 1990 Aug;76(2):302-7
2371035
Am Fam Physician. 2002 Oct 1;66(7):1239-48
12387436
Br J Nutr. 1999 Jan;81(1):7-20
10341670
Obstet Gynecol Surv. 1990 Apr;45(4):220-8
2181358
Clin Obstet Gynecol. 1983 Sep;26(3):710-8
6352130
J Reprod Med. 1983 Jul;28(7):465-8
6350579
J Clin Psychiatry. 2006 Oct;67(10):1624-32
17107257
Fortschr Med. 1997 Feb 28;115(6):9, 12
9173016
Arch Farmacol Toxicol. 1982 Aug;8(2):51-76
6818907
JAMA. 1990 Jul 18;264(3):387
2362336
Am J Psychiatry. 1999 Sep;156(9):1403-8
10484952
Am J Obstet Gynecol. 1984 Oct 15;150(4):363-6
6091462
Practitioner. 1984 Apr;228(1390):425-7
6539473
J Assoc Physicians India. 2006 Apr;54:309-19
16944615
Am J Psychiatry. 2004 Feb;161(2):343-51
14754784